N-(2-amino-2-oxoethyl)-1H-indole-2-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2-amino-2-oxoethyl)-1H-indole-2-carboxamide
• 化学式: C₁₁H₁₁N₃O₂
• mdl: MFCD12193623
• 分子量: 217.22
• InChiKey: DZTRDHWRJJQCJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  88
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• [EN] PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES<br/>[FR] HYDRAZIDES D'ACIDE PYRROLOPYRIDINE-2-CARBOXYLIQUE UTILISES COMME INHIBITEURS DE LA GLYCOGENE PHOSPHORYLASE
  申请人：PROSIDION LTD

  公开号：WO2005085245A1

  公开（公告）日：2005-09-15

  Compounds of Formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth.

  化合物式(I)或其药用可接受的盐是糖原磷酸化酶的抑制剂，可用于预防或治疗糖尿病、高血糖、高胆固醇血症、高胰岛素血症、高脂血症、高血压、动脉粥样硬化或组织缺血，例如心肌缺血，或作为心脏保护剂或异常细胞生长的抑制剂。
• Antidiabetic agents
  申请人：Pfizer Products Inc.

  公开号：EP1340500A1

  公开（公告）日：2003-09-03

  A compound of the formula wherein n, m, Z, R1, R5, R8, R9, R10 and R11 are as defined above, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly myocardial ischemia.

  一种具有上述定义的化合物的分子式，用于治疗糖尿病、胰岛素抵抗、糖尿病神经病变、糖尿病肾病、糖尿病视网膜病变、白内障、高血糖、高胆固醇血症、高血压、高胰岛素血症、高脂血症、动脉粥样硬化和组织缺血，特别是心肌缺血。
• [EN] CARBOXAMIDE DERIVATIVES AS ANTI-DIABETIC AGENTS<br/>[FR] DERIVES DE CARBOXAMIDE EN TANT QU'AGENTS ANTI-DIABETIQUES
  申请人：PFIZER PROD INC

  公开号：WO2004092158A1

  公开（公告）日：2004-10-28

  The present invention provides compounds of formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and produgs; wherein R1, R2, Ra, Rb, X, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.

  本发明提供了公式(I)的化合物，其立体异构体和前药，以及化合物，立体异构体和前药的药学上可接受的盐；其中R1，R2，Ra，Rb，X和Z如本文所定义；其制备的制药组合物；以及其用途。
• Anti-diabetic agents
  申请人：Pfizer Inc

  公开号：US20040220229A1

  公开（公告）日：2004-11-04

  The invention provides compounds of formula (I) 1 the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs; wherein R′, R″, R′″, X, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof in treating diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia.

  本发明提供了式(I)1的化合物及其前药和药物可接受的盐；其中R'，R"，R'"，X和Z的定义如本文所述；其药物组合物；以及在治疗糖尿病，胰岛素抵抗，糖尿病神经病变，糖尿病肾病，糖尿病视网膜病变，白内障，高血糖，高胆固醇血症，高血压，高胰岛素血症，高脂血症，动脉硬化和组织缺血中的用途。
• Benzazepine Ketone Compounds as Glycogen Phosphorylase Inhibitor, Preparation Method therefor, and Medical Uses
  申请人：CHENGDE MEDICAL UNIVERSITY

  公开号：US20160229848A1

  公开（公告）日：2016-08-11

  The present invention relates to the field of pharmaceutical chemistry, and particularly to a novel class of benzazepine ketone derivatives (I), their preparation method and their pharmaceutical uses. The compounds have glycogen phosphorylase inhibiting effect and can be used in the preparation of anti-diabetes and its complications medicaments, anti-cerebral ischemia medicaments, anti-cardiovascular diseases medicaments, blood lipid-lowering medicaments, weight-reducing medicaments, anti-atherosclerosis medicaments, medicaments for treating metabolic syndrome or anti-tumor medicaments. The present invention also relates to a preparation method of the class of compounds and pharmaceutical formulations containing the same.

  本发明涉及药物化学领域，特别是一种新颖的苯并噁唑酮衍生物（I），其制备方法及其药物用途。该化合物具有糖原磷酸化酶抑制作用，可用于制备抗糖尿病及其并发症药物、抗脑缺血药物、抗心血管疾病药物、降血脂药物、减肥药物、抗动脉粥样硬化药物、治疗代谢综合征的药物或抗肿瘤药物。本发明还涉及一种该类化合物的制备方法和含有该化合物的药物配方。